Skip to main content

Main menu

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
  • Other Publications
    • www.clevelandclinic.org

User menu

  • Register
  • Log in

Search

  • Advanced search
Cleveland Clinic Journal of Medicine
  • Other Publications
    • www.clevelandclinic.org
  • Register
  • Log in
Cleveland Clinic Journal of Medicine

Advanced Search

  • Home
  • Content
    • Current Issue
    • Ahead of Print
    • Past Issues
    • Supplements
    • Article Type
  • Specialty
    • Articles by Specialty
  • CME/MOC
    • Articles
    • Calendar
  • Info For
    • Manuscript Submission
    • Authors & Reviewers
    • Subscriptions
    • About CCJM
    • Contact Us
    • Media Kit
  • Conversations with Leaders
  • Conference Coverage
    • Kidney Week 2025
    • ACR Convergence 2025
    • Kidney Week 2024
    • CHEST 2024
    • ACR Convergence 2023
    • Kidney Week 2023
    • ObesityWeek 2023
    • IDWeek 2023
    • CHEST 2023
    • MDS 2023
    • IAS 2023
    • ACP 2023
    • AAN 2023
    • ACC / WCC 2023
    • AAAAI Meeting 2023
Commentary

Vaccine hesitancy: Where are we heading?

Sherif Beniameen Mossad, MD
Cleveland Clinic Journal of Medicine January 2026, 93 (1) 21-26; DOI: https://doi.org/10.3949/ccjm.93a.25104
Sherif Beniameen Mossad
Department of Infectious Diseases, Section of Transplant Infectious Diseases, Integrated Hospital Care Institute & Transplant Center, Cleveland Clinic, Cleveland, OH; Professor of Medicine, Cleveland Clinic Lerner College of Medicine of Case Western Reserve University School of Medicine, Cleveland, OH
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: mossads{at}ccf.org
  • Find this author on Cleveland Clinic
  • Article
  • Figures & Data
  • Info & Metrics
  • PDF
Loading

For the past 3 decades, I have cared for transplant candidates and recipients, who receive immunosuppressive drugs to prevent rejection but which place them at risk of infections. More than most other patients, they need vaccinations, per national guidelines,1,2 but their vaccination rates remain suboptimal, both here and in other countries.3,4 Personally, I’m encountering many patients who decline some and occasionally all vaccinations, something that rarely occurred just 10 years ago.

My experience reflects a disturbing global trend toward vaccine hesitancy, defined as delaying or refusing available vaccinations,5 or indecisiveness regarding a vaccination decision, independent of behavior.6 Reflecting an extreme form of vaccine hesitancy, anti-vaxxers or antivaccinationists are fundamentally and actively opposed to vaccination,7 often using social media to advance their views.8

Not long ago, we hailed vaccination as one of the top 10 public health achievements in the 20th century.9 Now, the World Health Organization lists vaccine hesitancy among the top 10 threats to global health.10

HOW DID WE GET HERE?

Vaccination skeptics appeared soon after Edward Jenner began advocating vaccination against smallpox at the turn of the 19th century.11 Nobody likes to be told what to do, and riots broke out in several towns in the United Kingdom when the first mandatory smallpox vaccination program was implemented.12 Antivaccination attitudes increased in Europe before gaining ground in the United States toward the end of the 19th century.13 Little did the skeptics know that this vaccine would eradicate this deadly infection from the face of the earth in less than 200 years.

Now, vaccine hesitancy is encountered among different countries, economies, religions, and cultures, and its scope varies depending on the extent of misinformation circulating in a given setting, as misinformation results in distrust, ultimately manifesting as “infodemics.”14–16 The United Nations Children’s Fund has reported that perception of the importance of childhood vaccines declined in 52 of 55 countries during the COVID-19 pandemic, and confidence in these vaccines declined by up to 44% in some countries.17

The messenger RNA (mRNA) vaccines against COVID-19 aroused special skepticism and conspiracy theories. This skepticism emerged even though these vaccines underwent rigorous studies conducted in multiple countries around the world; the technology underlying mRNA vaccines has been studied in other settings for 3 decades; and there is ample evidence for the safety, immunogenicity, efficacy, and effectiveness18,19 of mRNA vaccines compared with other vaccine production methods (Table 1). Patients opposed to mRNA COVID-19 vaccines can now receive Novavax’s Nuvaxovid protein-based subunit vaccine. The estimated prevalence of COVID-19 vaccine hesitancy in the United States varies widely by area, ranging from 2.6% to 26%.20

View this table:
  • View inline
  • View popup
TABLE 1

Messenger RNA (mRNA) vaccines vs other types of vaccines

In addition to the 2 mRNA COVID-19 vaccines, an mRNA respiratory syncytial virus vaccine is approved by the US Food and Drug Administration. A recently published randomized blinded study in healthy adults demonstrated the immunogenicity and efficacy of an mRNA influenza vaccine compared with inactivated influenza vaccine in preventing laboratory-confirmed influenza-like illness, with higher local and systemic reactogenicity within 7 days with the mRNA influenza vaccine but similar serious, severe, and life-threatening adverse events, including those leading to withdrawal from the study.21

Altogether more than 100 vaccines are licensed for use in the United States.22 In development are several more addressing common infections such as urinary tract infections23 and global infections such as malaria,24 dengue,25 chikungunya,26 and Salmonella enterica Paratyphi A.27

Nonetheless, the current state of affairs in vaccination is chaotic and evolving. On September 3, 2025, Florida became the first state to eliminate all vaccination mandates, including those for school children.28 Just 2 weeks later, the Centers for Disease Control and Prevention’s Advisory Committee on Immunization Practices (ACIP) moved from recommending COVID-19 vaccine for everyone to an individualized decision-making approach.29 In response, national and local medical societies issued declarations opposing this move,30 warning of politicization of the Department of Health and Human Services,31 and intensifying public-facing statements and programs supporting evidence-based vaccination guidelines.31–33 On December 4, 2025, the ACIP changed its recommendation for hepatitis B vaccination for newborns—formerly recommended for all, it is now optional if the mother tests negative for hepatitis B.34

WHAT’S AT STAKE?

What’s at stake is not only the reversal of vaccine-associated life-expectancy gains but also the reversal of noncommunicable diseases, particularly cardiovascular disease–associated life expectancy. To put it bluntly, people could die.

Measles is back

In 2000, the World Health Organization declared that measles had been eliminated in the United States. But it is back.

As of December 9, 2025, a total of 1,912 confirmed cases of measles had been reported in the United States in 2025; 92% of these cases were in people who were unvaccinated or of unknown vaccination status.35 Some 47 outbreaks had been reported in 43 jurisdictions, with 88% of confirmed cases being outbreak associated. These numbers are up from past years. Texas reported the highest number of confirmed cases (803), and New Mexico, Arizona, and Utah each reported more than 100 cases. Three quarters of cases in 2025 occurred in people older than 5 years, and 12% of patients required hospitalization. Three people have died.

The mumps, measles, and rubella vaccine is very safe, but it is most effective when more than 95% of people in a community are vaccinated. Unfortunately, only 10 states achieved this herd immunity target in 2023–2024, leaving 280,000 unvaccinated kindergartners at risk and serving as sources of further spread to adults with no or waning immunity. Pockets of unvaccinated people exist even in states with high vaccination coverage, such as New Mexico, leading to outbreaks.35

COVID-19, flu, and respiratory syncytial virus harm the heart

About two thirds of US adults have at least 1 risk factor for cardiovascular diseases.36 To the traditional risk factors such as high blood pressure we should add vaccine-preventable acute viral respiratory infections, including COVID-19, influenza, and respiratory syncytial virus.37 Deaths from noncommunicable diseases are continuing to decline around the world,38 but vaccine hesitancy could slow or reverse this trend.

COVID-19 is receding but not gone

Life expectancy decreased globally during the COVID-19 pandemic, then returned to prepandemic levels in 2023.39 In 2021, COVID-19 became the second-leading cause of death worldwide, particularly impacting lower-middle-income and high-income countries.40 In the United States, COVID-19 moved down to the tenth leading cause of death in 2023.41

Flu is an eternal threat, and bird flu looms

The influenza-associated hospitalization rate in the 2024–2025 influenza season was the highest since the 2009 influenza pandemic. Of those hospitalized with the flu, most had at least 1 underlying medical condition or were age 75 years or older, 17% were admitted to an intensive care unit, 6% received invasive mechanical ventilation, and 3% died during hospitalization.42

In the same season, pediatric influenza-associated encephalopathy occurred in 109 children, 19% of whom died, including 41% of those with acute necrotizing encephalopathy.43 Only 16% of these children had received an influenza vaccine earlier that season.

H5 bird flu is widespread in wild birds worldwide, and for the fourth year in a row it has caused outbreaks in US poultry and dairy cows and sporadic human cases, mostly in poultry and dairy workers, posing low risk to the public.44 The US Centers for Disease Control and Prevention is using surveillance systems to monitor H5 bird flu activity in humans, particularly in those with animal exposures. This virus can mutate and become more transmissible from animals to humans.45 Currently, the risk of transmission to people in the United States is mainly in those in contact with infected animals or contaminated surfaces, and the risk to the general population or of human-to-human transmission is low.46

WHAT PHYSICIANS CAN DO ABOUT VACCINE HESITANCY

Identifying causes of any problem, particularly potentially reversible causes, is the first step in attempting to find solutions.15,16,47,48

Identify and address external barriers to vaccination, such as misinformation, access, cost, and lack of community support.

Present vaccination as the default, rather than optional. Some patients are “hesitant adopters”49 who say they are hesitant but do not actually hold the opinion strongly and get the shot anyway. Sociodemographic factors affect hesitant adopters to different degrees. Clinician recommendations, conversations with friends and family, professional network interactions, workplace recommendations and requirements, and perceived social norms are important factors persuading those who are hesitant to become hesitant adopters (Table 2).

View this table:
  • View inline
  • View popup
TABLE 2

10 Reasons to get vaccinated

Humans cherish their freedom to make their own decisions. In general, positive reinforcement and incentives are more successful than negative reinforcement and punitive actions.

In any event, most people are not hesitant: 84% of Americans are extremely or somewhat confident in the effectiveness of childhood vaccines, and 75% extremely or somewhat agree that they have been tested enough for safety.50

Be equipped to answer our patients’ questions about vaccinations,51,52 using simple infographics, tailored to specific communities and cultures to facilitate conversations. Our recommendations must always be rooted in evidence-based data.53,54

Honestly present how the benefits dwarf potential risks. This builds trust, arguably the most important ingredient in establishing a healthy relationship between clinicians and their patients. Some vaccines decrease the risk of hospitalization and death from infection, even if they do not decrease the risk of acquiring infection. This is still valuable and clinically relevant! Also, vaccination can benefit not only the recipient but also the family and community at large, an argument that appeals to one’s sense of altruism and citizenship.

All approved vaccines have side effects to some degree, but objectively their benefits clearly outweigh their risks. Reassure patients that the preapproval and postapproval vaccine safety system is robust.55,56

Find allies and resources. Providing vaccines at a variety of places in addition to traditional medical offices and vaccination clinics, including emergency departments, schools, and places of work, at no or minimal cost and at extended hours, has been extensively studied and proven effective in increasing vaccination rates.

In an effort to protect their grandchildren through vaccines, grandparents have united in a volunteer-led movement to share personal stories of how vaccines developed before and during their lifetime changed their world (grandparentsforvaccines.com). Training community vaccination champions, such as public officeholders, clergy, teachers, and industry leaders, increases public trust in the value of vaccinations.

With the increasing demands on clinicians’ time,57 we need to use all available resources to stem the tide of vaccine hesitancy and change course from where we could be heading to where we should be heading.

DISCLOSURES

The author reports no relevant financial relationships which, in the context of their contributions, could be perceived as a potential conflict of interest.

  • Copyright © 2026 The Cleveland Clinic Foundation. All Rights Reserved.

REFERENCES

  1. ↵
    1. Radcliffe C,
    2. Kotton CN
    . Vaccination strategies for solid organ transplant candidates and recipients: insights and recommendations. Expert Rev Vaccines 2025; 24(1):313–323. doi:10.1080/14760584.2025.2489659
    OpenUrlCrossRefPubMed
  2. ↵
    1. Silva-Pinto A,
    2. Abreu I,
    3. Martins A,
    4. Bastos J,
    5. Araújo J,
    6. Pinto R
    . Vaccination after haematopoietic stem cell transplant: a review of the literature and proposed vaccination protocol. Vaccines (Basel) 2024; 12(12):1449. doi:10.3390/vaccines12121449
    OpenUrlCrossRefPubMed
  3. ↵
    1. Remane Y,
    2. Klaus VC,
    3. Heinitz K, et al
    . Assessment of vaccination rates and motivation among transplant patients using vaccination cards and interviews. Sci Rep 2025; 15(1):16911. doi:10.1038/s41598-025-01491-4
    OpenUrlCrossRefPubMed
  4. ↵
    1. Bouzas-Rodríguez A,
    2. Molina-Romera G,
    3. Vázquez-Lago JM,
    4. Vázquez-Cancela O,
    5. Fernández-Pérez C
    . Vaccination coverage in hematopoietic stem cell transplant patients. Vaccines (Basel) 2025; 13(3):257. doi:10.3390/vaccines13030257
    OpenUrlCrossRefPubMed
  5. ↵
    1. MacDonald NE; SAGE Working Group on Vaccine Hesitancy
    . Vaccine hesitancy: definition, scope and determinants. Vaccine 2015; 33(34):4161–4164. doi:10.1016/j.vaccine.2015.04.036
    OpenUrlCrossRefPubMed
  6. ↵
    1. Bussink-Voorend D,
    2. Hautvast JLA,
    3. Vandeberg L,
    4. Visser O,
    5. Hulscher MEJL
    . A systematic literature review to clarify the concept of vaccine hesitancy. Nat Hum Behav 2022; 6(12):1634–1648. doi:10.1038/s41562-022-01431-6
    OpenUrlCrossRefPubMed
  7. ↵
    1. Gallegos M,
    2. de Castro Pecanha V,
    3. Caycho-Rodríguez T
    . Anti-vax: the history of a scientific problem. J Public Health (Oxf) 2023; 45(1):e140–e141. doi:10.1093/pubmed/fdac048
    OpenUrlCrossRefPubMed
  8. ↵
    1. Benoit SL,
    2. Mauldin RF
    . The "anti-vax" movement: a quantitative report on vaccine beliefs and knowledge across social media. BMC Public Health 2021; 21(1):2106. doi:10.1186/s12889-021-12114-8
    OpenUrlCrossRefPubMed
  9. ↵
    1. Centers for Disease Control and Prevention (CDC)
    . Ten great public health achievements—United States, 1900-1999. MMWR Morb Mortal Wkly Rep 1999; 48(12):241–243. pmid:10220250
    OpenUrlPubMed
  10. ↵
    1. World Health Organization
    . Ten threats to global health in 2019. www.who.int/news-room/spotlight/ten-threats-to-global-health-in-2019. Accessed December 12, 2025.
  11. ↵
    1. Riedel S
    . Edward Jenner and the history of smallpox and vaccination. Proc (Bayl Univ Med Cent) 2005; 18(1):21–25. doi:10.1080/08998280.2005.11928028
    OpenUrlCrossRefPubMed
  12. ↵
    1. Durbach N
    . ‘They might as well brand us’: working-class resistance to compulsory vaccination in Victorian England. Soc Hist Med 2000; 13(1):45–62. doi:10.1093/shm/13.1.45
    OpenUrlCrossRefPubMed
  13. ↵
    1. Prabhu M
    . The long view: Ye old anti-vaxxers. Gavi. April 14, 2021. www.gavi.org/vaccineswork/ye-olde-anti-vaxxers. Accessed December 12, 2025.
  14. ↵
    1. Nuwarda RF,
    2. Ramzan I,
    3. Weekes L,
    4. Kayser V
    . Vaccine hesitancy: Contemporary issues and historical background. Vaccines (Basel) 2022; 10(10):1595. doi:10.3390/vaccines10101595
    OpenUrlCrossRefPubMed
  15. ↵
    1. Shah GH,
    2. Nguyen TH
    . Vaccine hesitancy through a global lens: cross-cultural evidence from a special issue. Vaccines (Basel) 2025; 13(5):529. doi:10.3390/vaccines13050529
    OpenUrlCrossRefPubMed
  16. ↵
    1. Dubé E,
    2. Gagnon D,
    3. Nickels E,
    4. Jeram S,
    5. Schuster M
    . Mapping vaccine hesitancy—country-specific characteristics of a global phenomenon. Vaccine 2014; 32(49):6649–6654. doi:10.1016/j.vaccine.2014.09.039
    OpenUrlCrossRefPubMed
  17. ↵
    1. UNICEF
    . New data indicates declining confidence in childhood vaccines of up to 44 percentage points in some countries during the COVID-19 pandemic. April 20, 2023. www.unicef.org/rosa/press-releases/new-data-indicates-declining-confidence-childhood-vaccines-44-percentage-points-some#. Accessed December 12, 2025.
  18. ↵
    1. Leong KY,
    2. Tham SK,
    3. Poh CL
    . Revolutionizing immunization: a comprehensive review of mRNA vaccine technology and applications. Virol J 2025; 22(1):71. doi:10.1186/s12985-025-02645-6
    OpenUrlCrossRefPubMed
  19. ↵
    1. Gote V,
    2. Bolla PK,
    3. Kommineni N, et al
    . A comprehensive review of mRNA vaccines. Int J Mol Sci 2023; 24(3):2700. doi:10.3390/ijms24032700
    OpenUrlCrossRefPubMed
  20. ↵
    1. Centers for Disease Control and Prevention
    . Estimates of vaccine hesitancy for COVID-19. https://data.cdc.gov/stories/s/Vaccine-Hesitancy-for-COVID-19/cnd2-a6zw/. Accessed December 12, 2025.
  21. ↵
    1. Fitz-Patrick D,
    2. McVinnie DS,
    3. Jackson LA, et al
    ; Pfizer C4781004 Trial Investigators. Efficacy, immunogenicity, and safety of modified mRNA influenza vaccine. N Engl J Med 2025; 393(20):2001–2011. doi:10.1056/NEJMoa2416779
    OpenUrlCrossRefPubMed
  22. ↵
    1. US Food & Drug Administration
    . Vaccines licensed for use in the United States. Updated May 25, 2025. www.fda.gov/vaccines-blood-biologics/vaccines/vaccines-licensed-use-united-states. Accessed December 12, 2025.
  23. ↵
    1. Palladino B,
    2. O’Shea-Farren D,
    3. Boan P, et al
    . Safety and efficacy of MV140 sublingual vaccine (Uromune) in preventing recurrent urine infections post renal transplant: a case series. Transpl Infect Dis 2025. Published online October 10, 2025. doi:10.1111/tid.70114
    OpenUrlCrossRef
  24. ↵
    1. Sallam M,
    2. Al-Khatib AO,
    3. Al-Mahzoum KS,
    4. Abdelaziz DH,
    5. Sallam M
    . Current developments in malaria vaccination: a concise review on implementation, challenges, and future directions. Clin Pharmacol 2025; 17:29–47. doi:10.2147/CPAA.S513282
    OpenUrlCrossRef
  25. ↵
    1. See KC
    . Dengue vaccination: a practical guide for clinicians. Vaccines (Basel) 2025; 13(2):145. doi:10.3390/vaccines13020145
    OpenUrlCrossRefPubMed
  26. ↵
    1. Weber WC,
    2. Streblow DN,
    3. Coffey LL
    . Chikungunya virus vaccines: a review of IXCHIQ and PXVX0317 from pre-clinical evaluation to licensure. BioDrugs 2024; 38(6):727–742. doi:10.1007/s40259-024-00677-y
    OpenUrlCrossRefPubMed
  27. ↵
    1. McCann N,
    2. Paganotti Vicentine M,
    3. Ebrahimi N, et al; VASP Study Team
    . Safety, efficacy, and immunogenicity of a Salmonella paratyphi A vaccine. N Engl J Med 2025; 393(17):1704–1714. doi:10.1056/NEJMoa2502992
    OpenUrlCrossRefPubMed
  28. ↵
    1. Fryhofer SA
    . AMA statement on Florida ending all vaccine mandates. September 3, 2025. American Medical Association. www.ama-assn.org/press-center/ama-press-releases/ama-statement-florida-ending-all-vaccine-mandates. Accessed December 12, 2025.
  29. ↵
    1. US Department of Health and Human Services
    . ACIP recommends COVID-19 immunization based on individual decision-making. September 19, 2025. www.hhs.gov/press-room/acip-recommends-covid19-vaccination-individual-decision-making.html. Accessed December 12, 2025.
  30. ↵
    1. National Foundation for Infectious Diseases
    . Staying on track: evidence-based vaccine recommendations. October 21, 2025. www.nfid.org/staying-on-track-evidence-based-vaccine-recommendations/. Accessed December 12, 2025.
  31. ↵
    1. Academy of Medicine of Cleveland & Northern Ohio
    . AMCNO advises public to follow vaccine schedule as usual, warns of politicization of Department of Health and Human Services (HHS), calls on RFK Jr. to resign. News release. Academy of Medicine of Cleveland & Northern Ohio. September 22, 2025. www.amcno.org/assets/PDFs/AMCNO%20Press%20Statement%20on%202025-2026%20Vaccine%20Schedule.pdf. Accessed December 12, 2025.
    1. Academy of Medicine of Cleveland & Northern Ohio
    . Why we vaccinate. www.amcno.org/why-we-vaccinate. Accessed December 12, 2025.
  32. ↵
    1. American Medical Association
    . Why vaccines matter to your health. 2025. www.ama-assn.org/system/files/vaccines-patients.pdf. Accessed December 12, 2025.
  33. ↵
    1. US Department of Health and Human Services
    . ACIP recommends individual-based decision-making for hepatitis B vaccine for infants born to women who test negative for the virus. December 5, 2025. www.hhs.gov/press-room/acip-recommends-individual-based-decision-making-hepatitis-b-vaccine-birth-dose-infants-born-women-test-negative-virus.html. Accessed December 12, 2025.
  34. ↵
    1. Centers for Disease Control and Prevention
    . Measles cases and outbreaks. Updated December 10, 2025. www.cdc.gov/measles/data-research/index.html. Accessed December 12, 2025.
  35. ↵
    1. Couch CA,
    2. Mascarenhas R,
    3. Stierman B,
    4. Fryar CD
    . Prevalence of cardiovascular disease risk factors in adults: United States, August 2021–August 2023. NCHS Data Brief 2025; (540):1–9. doi:10.15620/cdc/174623
    OpenUrlCrossRef
  36. ↵
    1. Kawai K,
    2. Muhere CF,
    3. Lemos EV,
    4. Francis JM
    . Viral Infections and risk of cardiovascular disease: systematic review and meta-analysis. J Am Heart Assoc 2025; 14(21):e042670. doi:10.1161/JAHA.125.042670
    OpenUrlCrossRefPubMed
  37. ↵
    1. NCD Countdown 2030 Collaborators
    . Benchmarking progress in non-communicable diseases: a global analysis of cause-specific mortality from 2001 to 2019. Lancet 2025; 406(10509):1255–1282. doi:10.1016/S0140-6736(25)01388-1
    OpenUrlCrossRefPubMed
  38. ↵
    1. GBD 2023 Demographics Collaborators
    . Global age-sex-specific all-cause mortality and life expectancy estimates for 204 countries and territories and 660 subnational locations, 1950–2023: a demographic analysis for the Global Burden of Disease Study 2023. Lancet 2025; 406(10513):1731–1810. doi:10.1016/S0140-6736(25)01330-3
    OpenUrlCrossRefPubMed
  39. ↵
    1. World Health Organization
    . The top 10 causes of death. August 7, 2024. www.who.int/news-room/fact-sheets/detail/the-top-10-causes-of-death. Accessed December 12, 2025.
  40. ↵
    1. Centers for Disease Control and Prevention
    . Mortality in the United States, 2023. Updated September 2024. www.cdc.gov/nchs/products/databriefs/db521.htm. Accessed December 12, 2025.
  41. ↵
    1. O’Halloran A,
    2. Habeck JW,
    3. Gilmer M, et al
    . Influenza-associated hospitalizations during a high severity season—influenza hospitalization surveillance network, United States, 2024–25 influenza season. MMWR Morb Mortal Wkly Rep 2025; 74:529–537. doi:10.15585/mmwr.mm7434a1
    OpenUrlCrossRefPubMed
  42. ↵
    1. Fazal A,
    2. Harker EJ,
    3. Neelam V, et al; CDC Influenza-Associated Encephalopathy Collaborators
    . Pediatric influenza-associated encephalopathy and acute necrotizing encephalopathy—United States, 2024–25 influenza season. MMWR Morb Mortal Wkly Rep 2025; 74(36):556–564. doi:10.15585/mmwr.mm7436a1
    OpenUrlCrossRefPubMed
  43. ↵
    1. Centers for Disease Control and Prevention
    . H5 bird flu: current situation. Updated November 24, 2025. www.cdc.gov/bird-flu/situation-summary/index.html. Accessed December 12, 2025.
  44. ↵
    1. Chen LL,
    2. Ip JD,
    3. Chan WM, et al
    . Enhanced replication of a contemporary avian influenza A H9N2 virus in human respiratory organoids. Emerg Microbes Infect 2025; 14(1):2576574. doi:10.1080/22221751.2025.2576574
    OpenUrlCrossRefPubMed
  45. ↵
    1. Centers for Disease Control and Prevention
    . Risk to people in the United States from highly pathogenic avian influenza A (H5N1) viruses. Updated February 28, 2025. www.cdc.gov/cfa-qualitative-assessments/php/data-research/h5-risk-assessment.html. Accessed December 12, 2025.
  46. ↵
    1. Shen SC,
    2. Dubey V
    . Addressing vaccine hesitancy: clinical guidance for primary care physicians working with parents. Can Fam Physician 2019; 65(3):175–181.
    OpenUrlAbstract/FREE Full Text
  47. ↵
    1. Tuckerman J,
    2. Kaufman J,
    3. Danchin M
    . Effective approaches to combat vaccine hesitancy. Pediatr Infect Dis J 2022; 41(5):e243–e245. doi:10.1097/INF.0000000000003499
    OpenUrlCrossRefPubMed
  48. ↵
    1. Willis DE,
    2. Moore R,
    3. Purvis RS,
    4. McElfish PA
    . Hesitant but vaccinated: lessons learned from hesitant adopters. Vaccine 2024; 42(20):126135. doi:10.1016/j.vaccine.2024.07.036
    OpenUrlCrossRefPubMed
  49. ↵
    1. Pew Research Center
    . How do Americans view childhood vaccines, vaccine research and policy? November 18, 2025. www.pewresearch.org/science/2025/11/18/how-do-americans-view-childhood-vaccines-vaccine-research-and-policy/. Accessed December 12, 2025.
  50. ↵
    1. American Medical Association
    . How to answer patients’ questions about vaccinations. Updated September 30, 2025. www.ama-assn.org/public-health/prevention-wellness/how-answer-patients-questions-about-vaccinations. Accessed December 12, 2025.
  51. ↵
    1. US Department of Health & Human Services
    . Talking to your patients about flu, COVID-19, and RSV vaccines. www.hhs.gov/sites/default/files/talking-your-patients.pdf. Accessed December 12, 2025.
  52. ↵
    1. Cai M,
    2. Xie Y,
    3. Al-Aly Z
    . Association of 2024–2025 Covid-19 vaccine with Covid-19 outcomes in US veterans. N Engl J Med 2025; 393(16):1612–1623. doi:10.1056/NEJMoa2510226
    OpenUrlCrossRef
  53. ↵
    1. Scott J,
    2. Abers MS,
    3. Marwah HK, et al
    . Updated evidence for Covid-19, RSV, and influenza vaccines for 2025–2026. N Engl J Med 2025; 393(22):2221–2242. doi:10.1056/NEJMsa2514268
    OpenUrlCrossRefPubMed
  54. ↵
    1. Centers for Disease Control and Prevention
    . Vaccine adverse event reporting system (VAERS). https://vaers.hhs.gov. Accessed December 12, 2025.
  55. ↵
    Combating vaccine revisionism. Nat Med 2025; 31(4):1039. doi:10.1038/s41591-025-03682-y
    OpenUrlCrossRefPubMed
  56. ↵
    1. Shackelford K
    . Vaccine Hesitancy, Provider Time, and Decision to Vaccinate. Dissertation. University of Missouri–St. Louis; 2023. https://irl.umsl.edu/dissertation/1353. Accessed December 12, 2025.
PreviousNext
Back to top

In this issue

Cleveland Clinic Journal of Medicine: 93 (1)
Cleveland Clinic Journal of Medicine
Vol. 93, Issue 1
1 Jan 2026
  • Table of Contents
  • Table of Contents (PDF)
  • Index by author
  • Complete Issue (PDF)
Print
Download PDF
Article Alerts
Sign In to Email Alerts with your Email Address
Email Article

Thank you for your interest in spreading the word on Cleveland Clinic Journal of Medicine.

NOTE: We only request your email address so that the person you are recommending the page to knows that you wanted them to see it, and that it is not junk mail. We do not capture any email address.

Enter multiple addresses on separate lines or separate them with commas.
Vaccine hesitancy: Where are we heading?
(Your Name) has sent you a message from Cleveland Clinic Journal of Medicine
(Your Name) thought you would like to see the Cleveland Clinic Journal of Medicine web site.
CAPTCHA
Please verify that you are a real person.
Citation Tools
Vaccine hesitancy: Where are we heading?
Sherif Beniameen Mossad
Cleveland Clinic Journal of Medicine Jan 2026, 93 (1) 21-26; DOI: 10.3949/ccjm.93a.25104

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
Share
Vaccine hesitancy: Where are we heading?
Sherif Beniameen Mossad
Cleveland Clinic Journal of Medicine Jan 2026, 93 (1) 21-26; DOI: 10.3949/ccjm.93a.25104
Twitter logo Facebook logo Mendeley logo
  • Tweet Widget

Jump to section

  • Article
    • HOW DID WE GET HERE?
    • WHAT’S AT STAKE?
    • WHAT PHYSICIANS CAN DO ABOUT VACCINE HESITANCY
    • DISCLOSURES
    • REFERENCES
  • Figures & Data
  • Info & Metrics
  • PDF

Related Articles

  • No related articles found.
  • PubMed
  • Google Scholar

Cited By...

  • No citing articles found.
  • Google Scholar

More in this TOC Section

  • Failure to thrive in hospitalized older adults: More than a ‘social admission’
  • Benzodiazepines: Caught between patient needs and guidelines
Show more Commentary

Similar Articles

Subjects

  • Infectious Diseases
  • Preventive Care

Navigate

  • Current Issue
  • Past Issues
  • Supplements
  • Article Type
  • Specialty
  • CME/MOC Articles
  • CME/MOC Calendar
  • Media Kit

Authors & Reviewers

  • Manuscript Submission
  • Authors & Reviewers
  • Subscriptions
  • About CCJM
  • Contact Us
  • Cleveland Clinic Center for Continuing Education
  • Consult QD

Share your suggestions!

Copyright © 2026 The Cleveland Clinic Foundation. All rights reserved. The information provided is for educational purposes only. Use of this website is subject to the website terms of use and privacy policy. 

Powered by HighWire